Equinor ASA (EQNR)

Total Costs & Expenses

$21.66B

Quarterly · Period ending: · USD

EQNR logo

EQNR Total Costs & Expenses

Latest reported$21.66B
EQNR Quarterly Total Costs & Expenses ($0.00 → $21.66B)
High-resolution chart · PNG

EQNR total costs & expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Equinor ASA Total Costs & Expenses — Quarterly (USD)
Period endingTotal Costs & Expenses (USD)
21,660,000,000
19,012,000,000
19,209,053,796
20,747,000,000
19,409,000,000
20,510,000,000
17,800,000,000
18,511,000,000
17,806,000,000
17,458,000,000
20,095,000,000
18,471,000,000
15,819,000,000
16,694,000,000
17,258,000,000
16,622,000,000
18,654,000,000
17,658,000,000
18,547,000,000
13,544,000,000
12,081,000,000
10,908,000,000
12,864,000,000
13,269,000,000
8,035,000,000
15,006,000,000
13,384,000,000
13,282,000,000
13,559,000,000
11,744,000,000
15,656,000,000
14,539,000,000
14,514,000,000
14,914,000,000
13,581,000,000
11,683,000,000
11,690,000,000
11,340,000,000
12,260,000,000
11,315,000,000
10,588,000,000
9,046,000,000
12,206,442,453
12,330,994,574
11,847,588,151
18,134,582,549
18,494,034,160
20,214,744,817
18,069,263,335
19,748,070,566
17,100,706,719
20,557,807,389
18,730,352,058
21,135,363,717
20,317,705,385
21,932,314,258
23,275,743,472
24,136,405,219
18,840,582,322
21,976,613,365
20,048,792,833
18,065,758,134
16,872,735,907
16,945,654,588
15,754,740,007
15,052,053,934
15,493,734,139
16,426,884,483
12,579,892,067
11,465,112,826
7,074,000,000
21,600,000,000
21,221,000,000
20,847,000,000
25,565,000,000
15,786,000,000
14,078,000,000
12,620,000,000
14,051,000,000
11,709,000,000
12,261,000,000
11,909,000,000
10,931,000,000
12,401,000,000
10,883,000,000
9,955,000,000
13,925,000,000
9,947,000,000
8,220,000,000
7,399,000,000
9,070,000,000
7,204,000,000
6,131,000,000
7,281,000,000
9,118,000,000
6,753,000,000
6,986,000,000
5,076,000,000
5,678,000,000
5,505,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.